Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA

Daniel Lynch, a Director at SpringWorks Therapeutics, Inc., has reported the disposition of all his common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025.

Summary

• Daniel Lynch, a Director of SpringWorks Therapeutics, Inc. (SWTX), disposed of all his beneficial ownership in the company's securities on July 1, 2025, due to the merger with Merck KGaA.
• The merger, pursuant to an Agreement and Plan of Merger dated April 27, 2025, resulted in SpringWorks Therapeutics becoming a wholly-owned subsidiary of Merck KGaA.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash per share.
• Lynch disposed of 93,004 shares of common stock, which included 10,060 shares underlying restricted stock units (RSUs).
• Outstanding RSUs, whether vested or unvested, were converted into Parent Cash-Based RSU Awards, entitling the holder to a cash amount equal to the Merger Consideration multiplied by the number of shares subject to the RSU.
• These Parent Cash-Based RSU Awards will generally vest according to their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger's closing date, subject to continued employment.
• Vested stock options were cancelled and converted into a cash amount equal to the product of the number of shares subject to the option and the excess of the Merger Consideration ($47.00) over the option's exercise price.
• Unvested stock options were converted into Parent Cash-Based Option Awards, with similar vesting terms to the RSU awards, including the 50% vesting on the nine-month anniversary of closing, subject to continued employment.
• Options with an exercise price greater than $47.00 per share were cancelled at the effective time of the merger for no consideration or payment.
• Lynch disposed of various stock options with exercise prices ranging from $1.65 to $44.77, totaling 317,578 underlying shares.

Sentiment

Score: 6

Explanation: The document reports the factual outcome of a merger, which provides liquidity to shareholders and converts unvested equity into cash-based awards, indicating a definitive and generally positive financial event for the reporting person, despite the loss of direct equity ownership.

Positives

• Shareholders, including the reporting person, received a cash payout of $47.00 per share for their common stock holdings.
• Unvested restricted stock units and stock options were converted into cash-based awards, providing a future cash payout opportunity for continued employment.
• The merger provides a clear exit strategy and liquidity for shareholders.

Negatives

• Options with an exercise price greater than the $47.00 merger consideration were cancelled for no value.
• The reporting person no longer holds direct equity in SpringWorks Therapeutics, Inc.
• Future vesting of cash-based awards is contingent upon continued employment with the acquiring entity.

Risks

• Continued employment is required for the full vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards.
• The value of options with an exercise price above the merger consideration was lost.

Future Outlook

SpringWorks Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck KGaA. Employees with unvested equity awards will receive cash-based awards that will continue to vest according to their original schedules, with a specific acceleration of 50% of unvested tranches on the nine-month anniversary of the merger closing, contingent on continued employment.

Industry Context

This transaction represents a significant consolidation event within the biotechnology and pharmaceutical sectors, where larger entities acquire smaller, innovative companies to expand their pipelines and market presence. Such mergers are common strategies for growth and portfolio diversification in the highly competitive life sciences industry.

Stakeholder Impact

• Shareholders: Received $47.00 cash per share for their common stock, providing liquidity.
• Employees (including the reporting person): Those with unvested equity awards had them converted into cash-based awards, with continued vesting contingent on employment, offering a retention mechanism.
• SpringWorks Therapeutics as an entity: Now operates as a wholly-owned subsidiary of Merck KGaA, losing its independent public company status.

Next Steps

• Continued vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards for eligible employees, subject to continued employment.
• 50% of each then-unvested tranche of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards will vest on the nine-month anniversary of the merger's closing date.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, Form 4, Insider Transaction, Beneficial Ownership, Stock Options, Restricted Stock Units, Corporate Action, Biotechnology, Pharmaceuticals